#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3.
1-1	0-2	3.	_	_	_	_

#Text=Discussion
2-1	3-13	Discussion	abstract	new	_	_

#Text=The statistical analysis of the collected data at each visit shows a very good trend for hydrogel containing trehalose and ceramides based ingredient
3-1	14-17	The	abstract[2]	new[2]	_	_
3-2	18-29	statistical	abstract[2]	new[2]	_	_
3-3	30-38	analysis	abstract[2]	new[2]	_	_
3-4	39-41	of	abstract[2]	new[2]	_	_
3-5	42-45	the	abstract[2]|abstract[3]	new[2]|new[3]	_	_
3-6	46-55	collected	abstract[2]|abstract[3]	new[2]|new[3]	_	_
3-7	56-60	data	abstract[2]|abstract[3]	new[2]|new[3]	_	_
3-8	61-63	at	abstract[2]|abstract[3]	new[2]|new[3]	_	_
3-9	64-68	each	abstract[2]|abstract[3]|event[4]	new[2]|new[3]|new[4]	coref	4-2[10_4]
3-10	69-74	visit	abstract[2]|abstract[3]|event[4]	new[2]|new[3]|new[4]	_	_
3-11	75-80	shows	_	_	_	_
3-12	81-82	a	abstract[5]	new[5]	_	_
3-13	83-87	very	abstract[5]	new[5]	_	_
3-14	88-92	good	abstract[5]	new[5]	_	_
3-15	93-98	trend	abstract[5]	new[5]	_	_
3-16	99-102	for	abstract[5]	new[5]	_	_
3-17	103-111	hydrogel	abstract[5]|substance[6]	new[5]|new[6]	coref	6-21[25_6]
3-18	112-122	containing	abstract[5]|substance[6]	new[5]|new[6]	_	_
3-19	123-132	trehalose	abstract[5]|substance[6]|substance|substance[9]	new[5]|new[6]|new|new[9]	coref|coref	6-21|6-21[24_9]
3-20	133-136	and	abstract[5]|substance[6]|substance[9]	new[5]|new[6]|new[9]	_	_
3-21	137-146	ceramides	abstract[5]|substance[6]|substance|substance[9]	new[5]|new[6]|new|new[9]	coref	6-19
3-22	147-152	based	abstract[5]|substance[6]|substance[9]	new[5]|new[6]|new[9]	_	_
3-23	153-163	ingredient	abstract[5]|substance[6]|substance[9]	new[5]|new[6]|new[9]	_	_

#Text=at each visit :
4-1	164-166	at	_	_	_	_
4-2	167-171	each	event[10]	giv[10]	coref	9-25[49_10]
4-3	172-177	visit	event[10]	giv[10]	_	_
4-4	178-179	:	_	_	_	_

#Text=Evaporimetry ( Transepidermal Water Loss ( TEWL ) )
5-1	180-192	Evaporimetry	abstract	new	coref	6-1
5-2	193-194	(	_	_	_	_
5-3	195-209	Transepidermal	place	new	coref	13-4
5-4	210-215	Water	_	_	_	_
5-5	216-220	Loss	_	_	_	_
5-6	221-222	(	_	_	_	_
5-7	223-227	TEWL	abstract	new	coref	13-8
5-8	228-229	)	_	_	_	_
5-9	230-231	)	_	_	_	_

#Text=Evaporimetry was used to detect any influence on the water barrier function of the skin following application of ceramides and trehalose based ingredient hydrogel and placebo hydrogel .
6-1	232-244	Evaporimetry	abstract	giv	coref	10-14
6-2	245-248	was	_	_	_	_
6-3	249-253	used	_	_	_	_
6-4	254-256	to	_	_	_	_
6-5	257-263	detect	_	_	_	_
6-6	264-267	any	abstract[15]	new[15]	_	_
6-7	268-277	influence	abstract[15]	new[15]	_	_
6-8	278-280	on	abstract[15]	new[15]	_	_
6-9	281-284	the	abstract[15]|abstract[18]	new[15]|new[18]	_	_
6-10	285-290	water	abstract[15]|substance|abstract[18]	new[15]|new|new[18]	coref	8-8[31_0]
6-11	291-298	barrier	abstract[15]|object|abstract[18]	new[15]|new|new[18]	coref	8-16[35_0]
6-12	299-307	function	abstract[15]|abstract[18]	new[15]|new[18]	_	_
6-13	308-310	of	abstract[15]|abstract[18]	new[15]|new[18]	_	_
6-14	311-314	the	abstract[15]|abstract[18]|object[19]	new[15]|new[18]|new[19]	coref	8-16[0_19]
6-15	315-319	skin	abstract[15]|abstract[18]|object[19]	new[15]|new[18]|new[19]	_	_
6-16	320-329	following	abstract[15]	new[15]	_	_
6-17	330-341	application	abstract[15]|event[20]	new[15]|new[20]	coref	12-3[0_20]
6-18	342-344	of	abstract[15]|event[20]	new[15]|new[20]	_	_
6-19	345-354	ceramides	abstract[15]|event[20]|substance|substance[22]	new[15]|new[20]|giv|giv[22]	coref|coref	6-19[22_0]|9-9[0_22]
6-20	355-358	and	abstract[15]|event[20]|substance[22]	new[15]|new[20]|giv[22]	_	_
6-21	359-368	trehalose	abstract[15]|event[20]|substance[22]|substance|substance[24]|substance[25]	new[15]|new[20]|giv[22]|giv|giv[24]|giv[25]	coref|coref|coref	6-26[27_25]|9-11|9-11[44_24]
6-22	369-374	based	abstract[15]|event[20]|substance[22]|substance[24]|substance[25]	new[15]|new[20]|giv[22]|giv[24]|giv[25]	_	_
6-23	375-385	ingredient	abstract[15]|event[20]|substance[22]|substance[24]|substance[25]	new[15]|new[20]|giv[22]|giv[24]|giv[25]	_	_
6-24	386-394	hydrogel	abstract[15]|event[20]|substance[22]|substance[25]	new[15]|new[20]|giv[22]|giv[25]	_	_
6-25	395-398	and	abstract[15]|event[20]|substance[22]	new[15]|new[20]|giv[22]	_	_
6-26	399-406	placebo	abstract[15]|event[20]|substance[22]|person|substance[27]	new[15]|new[20]|giv[22]|new|giv[27]	coref|coref	9-7[40_27]|9-15
6-27	407-415	hydrogel	abstract[15]|event[20]|substance[22]|substance[27]	new[15]|new[20]|giv[22]|giv[27]	_	_
6-28	416-417	.	_	_	_	_

#Text=Corneometry ( Hydration )
7-1	418-429	Corneometry	abstract	new	appos	7-3
7-2	430-431	(	_	_	_	_
7-3	432-441	Hydration	abstract	giv	coref	8-20
7-4	442-443	)	_	_	_	_

#Text=In order to measure the amount of water present in the stratum corneum and the skin barrier condition , hydration has been evaluated through Corneometry .
8-1	444-446	In	_	_	_	_
8-2	447-452	order	_	_	_	_
8-3	453-455	to	_	_	_	_
8-4	456-463	measure	_	_	_	_
8-5	464-467	the	substance[30]	new[30]	coref	23-19[130_30]
8-6	468-474	amount	substance[30]	new[30]	_	_
8-7	475-477	of	substance[30]	new[30]	_	_
8-8	478-483	water	substance[30]|substance[31]	new[30]|giv[31]	coref	13-5[0_31]
8-9	484-491	present	substance[30]|substance[31]	new[30]|giv[31]	_	_
8-10	492-494	in	substance[30]|substance[31]	new[30]|giv[31]	_	_
8-11	495-498	the	substance[30]|substance[31]|place[33]	new[30]|giv[31]|new[33]	_	_
8-12	499-506	stratum	substance[30]|substance[31]|place|place[33]	new[30]|giv[31]|new|new[33]	_	_
8-13	507-514	corneum	substance[30]|substance[31]|place[33]	new[30]|giv[31]|new[33]	_	_
8-14	515-518	and	substance[30]|substance[31]	new[30]|giv[31]	_	_
8-15	519-522	the	substance[30]|substance[31]|abstract[36]	new[30]|giv[31]|new[36]	_	_
8-16	523-527	skin	substance[30]|substance[31]|object|object[35]|abstract[36]	new[30]|giv[31]|giv|giv[35]|new[36]	coref|coref	10-17[0_35]|10-30
8-17	528-535	barrier	substance[30]|substance[31]|object[35]|abstract[36]	new[30]|giv[31]|giv[35]|new[36]	_	_
8-18	536-545	condition	substance[30]|substance[31]|abstract[36]	new[30]|giv[31]|new[36]	_	_
8-19	546-547	,	_	_	_	_
8-20	548-557	hydration	abstract	giv	coref	8-25
8-21	558-561	has	_	_	_	_
8-22	562-566	been	_	_	_	_
8-23	567-576	evaluated	_	_	_	_
8-24	577-584	through	_	_	_	_
8-25	585-596	Corneometry	abstract	giv	coref	10-12
8-26	597-598	.	_	_	_	_

#Text=Moreover , the T-test applied to hydrogel containing ceramides and trehalose based ingredient and placebo formula gave a statistically significant difference between them at each visit , always showing better results for the hydrogel containing ceramides and trehalose based ingredient .
9-1	599-607	Moreover	_	_	_	_
9-2	608-609	,	_	_	_	_
9-3	610-613	the	abstract[39]	new[39]	_	_
9-4	614-620	T-test	abstract[39]	new[39]	_	_
9-5	621-628	applied	abstract[39]	new[39]	_	_
9-6	629-631	to	abstract[39]	new[39]	_	_
9-7	632-640	hydrogel	abstract[39]|substance[40]	new[39]|giv[40]	coref	9-33[51_40]
9-8	641-651	containing	abstract[39]|substance[40]	new[39]|giv[40]	_	_
9-9	652-661	ceramides	abstract[39]|substance[40]|substance|substance[42]	new[39]|giv[40]|giv|giv[42]	coref|coref	9-9[42_0]|9-36[0_42]
9-10	662-665	and	abstract[39]|substance[40]|substance[42]	new[39]|giv[40]|giv[42]	_	_
9-11	666-675	trehalose	abstract[39]|substance[40]|substance[42]|substance|substance[44]	new[39]|giv[40]|giv[42]|giv|giv[44]	coref|coref	9-38|9-38[55_44]
9-12	676-681	based	abstract[39]|substance[40]|substance[42]|substance[44]	new[39]|giv[40]|giv[42]|giv[44]	_	_
9-13	682-692	ingredient	abstract[39]|substance[40]|substance[42]|substance[44]	new[39]|giv[40]|giv[42]|giv[44]	_	_
9-14	693-696	and	abstract[39]|substance[40]|substance[42]	new[39]|giv[40]|giv[42]	_	_
9-15	697-704	placebo	abstract[39]|substance[40]|substance[42]|person|abstract[46]	new[39]|giv[40]|giv[42]|giv|new[46]	coref|coref	11-22|12-6[79_46]
9-16	705-712	formula	abstract[39]|substance[40]|substance[42]|abstract[46]	new[39]|giv[40]|giv[42]|new[46]	_	_
9-17	713-717	gave	_	_	_	_
9-18	718-719	a	abstract[47]	new[47]	ana	9-23[0_47]
9-19	720-733	statistically	abstract[47]	new[47]	_	_
9-20	734-745	significant	abstract[47]	new[47]	_	_
9-21	746-756	difference	abstract[47]	new[47]	_	_
9-22	757-764	between	abstract[47]	new[47]	_	_
9-23	765-769	them	abstract[47]|abstract	new[47]|giv	_	_
9-24	770-772	at	_	_	_	_
9-25	773-777	each	event[49]	giv[49]	coref	11-13[71_49]
9-26	778-783	visit	event[49]	giv[49]	_	_
9-27	784-785	,	_	_	_	_
9-28	786-792	always	_	_	_	_
9-29	793-800	showing	_	_	_	_
9-30	801-807	better	abstract[50]	new[50]	coref	11-1[68_50]
9-31	808-815	results	abstract[50]	new[50]	_	_
9-32	816-819	for	_	_	_	_
9-33	820-823	the	substance[51]	giv[51]	_	_
9-34	824-832	hydrogel	substance[51]	giv[51]	_	_
9-35	833-843	containing	substance[51]	giv[51]	_	_
9-36	844-853	ceramides	substance[51]|substance|substance[53]	giv[51]|giv|giv[53]	coref|coref	9-36[53_0]|10-27[0_53]
9-37	854-857	and	substance[51]|substance[53]	giv[51]|giv[53]	_	_
9-38	858-867	trehalose	substance[51]|substance[53]|substance|substance[55]	giv[51]|giv[53]|giv|giv[55]	coref|coref	10-25|11-10[70_55]
9-39	868-873	based	substance[51]|substance[53]|substance[55]	giv[51]|giv[53]|giv[55]	_	_
9-40	874-884	ingredient	substance[51]|substance[53]|substance[55]	giv[51]|giv[53]|giv[55]	_	_
9-41	885-886	.	_	_	_	_

#Text=The double-blind , placebo-controlled study was performed to assess , by corneometry and evaporimetry , the barrier normalizing efficacy of a topical product containing trehalose and ceramides to alleviate skin dryness on limbs .
10-1	887-890	The	abstract[56]	new[56]	coref	11-2[0_56]
10-2	891-903	double-blind	abstract[56]	new[56]	_	_
10-3	904-905	,	abstract[56]	new[56]	_	_
10-4	906-924	placebo-controlled	abstract[56]	new[56]	_	_
10-5	925-930	study	abstract[56]	new[56]	_	_
10-6	931-934	was	_	_	_	_
10-7	935-944	performed	_	_	_	_
10-8	945-947	to	_	_	_	_
10-9	948-954	assess	_	_	_	_
10-10	955-956	,	_	_	_	_
10-11	957-959	by	_	_	_	_
10-12	960-971	corneometry	abstract	giv	coref	17-1
10-13	972-975	and	_	_	_	_
10-14	976-988	evaporimetry	abstract	giv	_	_
10-15	989-990	,	_	_	_	_
10-16	991-994	the	abstract[60]	new[60]	_	_
10-17	995-1002	barrier	object|abstract[60]	giv|new[60]	coref	20-36[106_0]
10-18	1003-1014	normalizing	abstract[60]	new[60]	_	_
10-19	1015-1023	efficacy	abstract[60]	new[60]	_	_
10-20	1024-1026	of	abstract[60]	new[60]	_	_
10-21	1027-1028	a	abstract[60]|substance[61]	new[60]|new[61]	coref	28-6[175_61]
10-22	1029-1036	topical	abstract[60]|substance[61]	new[60]|new[61]	_	_
10-23	1037-1044	product	abstract[60]|substance[61]	new[60]|new[61]	_	_
10-24	1045-1055	containing	abstract[60]|substance[61]	new[60]|new[61]	_	_
10-25	1056-1065	trehalose	abstract[60]|substance[61]|substance	new[60]|new[61]|giv	coref	12-11
10-26	1066-1069	and	abstract[60]|substance[61]	new[60]|new[61]	_	_
10-27	1070-1079	ceramides	abstract[60]|substance[61]|substance	new[60]|new[61]|giv	coref	12-13
10-28	1080-1082	to	_	_	_	_
10-29	1083-1092	alleviate	_	_	_	_
10-30	1093-1097	skin	object|abstract[65]	giv|new[65]	coref	20-32[105_0]
10-31	1098-1105	dryness	abstract[65]	new[65]	_	_
10-32	1106-1108	on	_	_	_	_
10-33	1109-1114	limbs	object	new	_	_
10-34	1115-1116	.	_	_	_	_

#Text=The study results show a significant moisturizing effect of the ingredient at each visit , both versus baseline and versus the placebo control ( p < 0.01 ) .
11-1	1117-1120	The	abstract[68]	giv[68]	coref	20-1[98_68]
11-2	1121-1126	study	abstract|abstract[68]	giv|giv[68]	coref	28-3[174_0]
11-3	1127-1134	results	abstract[68]	giv[68]	_	_
11-4	1135-1139	show	_	_	_	_
11-5	1140-1141	a	abstract[69]	new[69]	coref	20-5[99_69]
11-6	1142-1153	significant	abstract[69]	new[69]	_	_
11-7	1154-1166	moisturizing	abstract[69]	new[69]	_	_
11-8	1167-1173	effect	abstract[69]	new[69]	_	_
11-9	1174-1176	of	abstract[69]	new[69]	_	_
11-10	1177-1180	the	abstract[69]|substance[70]	new[69]|giv[70]	coref	12-10[82_70]
11-11	1181-1191	ingredient	abstract[69]|substance[70]	new[69]|giv[70]	_	_
11-12	1192-1194	at	abstract[69]	new[69]	_	_
11-13	1195-1199	each	abstract[69]|event[71]	new[69]|giv[71]	_	_
11-14	1200-1205	visit	abstract[69]|event[71]	new[69]|giv[71]	_	_
11-15	1206-1207	,	abstract[69]	new[69]	_	_
11-16	1208-1212	both	abstract[69]|abstract[72]	new[69]|new[72]	_	_
11-17	1213-1219	versus	abstract[69]|abstract[72]	new[69]|new[72]	_	_
11-18	1220-1228	baseline	abstract[69]|abstract[72]	new[69]|new[72]	_	_
11-19	1229-1232	and	_	_	_	_
11-20	1233-1239	versus	_	_	_	_
11-21	1240-1243	the	abstract[74]	new[74]	_	_
11-22	1244-1251	placebo	person|abstract[74]	giv|new[74]	coref	24-15[147_0]
11-23	1252-1259	control	abstract[74]	new[74]	_	_
11-24	1260-1261	(	_	_	_	_
11-25	1262-1263	p	abstract	new	coref	27-14[171_0]
11-26	1264-1265	<	_	_	_	_
11-27	1266-1270	0.01	abstract	new	_	_
11-28	1271-1272	)	_	_	_	_
11-29	1273-1274	.	_	_	_	_

#Text=For the application site of topical cosmetic formula containing a trehalose and ceramides based ingredient :
12-1	1275-1278	For	_	_	_	_
12-2	1279-1282	the	place[78]	new[78]	coref	29-26[200_78]
12-3	1283-1294	application	event|place[78]	giv|new[78]	coref	31-6
12-4	1295-1299	site	place[78]	new[78]	_	_
12-5	1300-1302	of	place[78]	new[78]	_	_
12-6	1303-1310	topical	place[78]|abstract[79]	new[78]|giv[79]	_	_
12-7	1311-1319	cosmetic	place[78]|abstract[79]	new[78]|giv[79]	_	_
12-8	1320-1327	formula	place[78]|abstract[79]	new[78]|giv[79]	_	_
12-9	1328-1338	containing	place[78]|abstract[79]	new[78]|giv[79]	_	_
12-10	1339-1340	a	place[78]|abstract[79]|substance[82]	new[78]|giv[79]|giv[82]	coref	22-16[123_82]
12-11	1341-1350	trehalose	place[78]|abstract[79]|substance|substance[82]	new[78]|giv[79]|giv|giv[82]	coref	22-16
12-12	1351-1354	and	place[78]|abstract[79]|substance[82]	new[78]|giv[79]|giv[82]	_	_
12-13	1355-1364	ceramides	place[78]|abstract[79]|substance|substance[82]	new[78]|giv[79]|giv|giv[82]	coref	22-18
12-14	1365-1370	based	place[78]|abstract[79]|substance[82]	new[78]|giv[79]|giv[82]	_	_
12-15	1371-1381	ingredient	place[78]|abstract[79]|substance[82]	new[78]|giv[79]|giv[82]	_	_
12-16	1382-1383	:	_	_	_	_

#Text=( 1 ) Transepidermal water loss ( TEWL ) value shows a reduction of −54 % after 4 weeks (
13-1	1384-1385	(	_	_	_	_
13-2	1386-1387	1	_	_	_	_
13-3	1388-1389	)	_	_	_	_
13-4	1390-1404	Transepidermal	place|abstract[85]|abstract[87]	giv|new[85]|new[87]	coref|coref|coref	23-37|23-35[136_85]|27-14[170_87]
13-5	1405-1410	water	substance|abstract[85]|abstract[87]	giv|new[85]|new[87]	coref	20-45[108_0]
13-6	1411-1415	loss	abstract[85]|abstract[87]	new[85]|new[87]	_	_
13-7	1416-1417	(	abstract[87]	new[87]	_	_
13-8	1418-1422	TEWL	abstract|abstract[87]	giv|new[87]	coref	23-41
13-9	1423-1424	)	abstract[87]	new[87]	_	_
13-10	1425-1430	value	abstract[87]	new[87]	_	_
13-11	1431-1436	shows	_	_	_	_
13-12	1437-1438	a	event[88]	new[88]	_	_
13-13	1439-1448	reduction	event[88]	new[88]	_	_
13-14	1449-1451	of	event[88]	new[88]	_	_
13-15	1452-1455	−54	event[88]|abstract[89]	new[88]|new[89]	coref	17-6[95_89]
13-16	1456-1457	%	event[88]|abstract[89]	new[88]|new[89]	_	_
13-17	1458-1463	after	_	_	_	_
13-18	1464-1465	4	time[90]	new[90]	coref	17-9[96_90]
13-19	1466-1471	weeks	time[90]	new[90]	_	_
13-20	1472-1473	(	_	_	_	_

#Text=Figure 2
14-1	1474-1480	Figure	abstract[91]	new[91]	_	_
14-2	1481-1482	2	abstract[91]	new[91]	_	_

#Text=) .
15-1	1483-1484	)	_	_	_	_
15-2	1485-1486	.	_	_	_	_

#Text=( 2 )
16-1	1487-1488	(	_	_	_	_
16-2	1489-1490	2	abstract	new	_	_
16-3	1491-1492	)	_	_	_	_

#Text=Hydration shows an increase of 102 % after 4 weeks (
17-1	1493-1502	Hydration	abstract	giv	coref	37-4[255_0]
17-2	1503-1508	shows	_	_	_	_
17-3	1509-1511	an	event[94]	new[94]	_	_
17-4	1512-1520	increase	event[94]	new[94]	_	_
17-5	1521-1523	of	event[94]	new[94]	_	_
17-6	1524-1527	102	event[94]|abstract[95]	new[94]|giv[95]	_	_
17-7	1528-1529	%	event[94]|abstract[95]	new[94]|giv[95]	_	_
17-8	1530-1535	after	_	_	_	_
17-9	1536-1537	4	time[96]	giv[96]	coref	26-20[161_96]
17-10	1538-1543	weeks	time[96]	giv[96]	_	_
17-11	1544-1545	(	_	_	_	_

#Text=Figure 3
18-1	1546-1552	Figure	abstract[97]	new[97]	_	_
18-2	1553-1554	3	abstract[97]	new[97]	_	_

#Text=) .
19-1	1555-1556	)	_	_	_	_
19-2	1557-1558	.	_	_	_	_

#Text=Such results point out the significant moisturizing effect after using the cosmetic under examination and go well with the rationale of the formulation , based on ingredients able to moisturize rapidly the skin and recover the cutaneous barrier to allow it to better hold the water present into its outer layers .
20-1	1559-1563	Such	abstract[98]	giv[98]	coref	26-2[154_98]
20-2	1564-1571	results	abstract[98]	giv[98]	_	_
20-3	1572-1577	point	_	_	_	_
20-4	1578-1581	out	_	_	_	_
20-5	1582-1585	the	abstract[99]	giv[99]	_	_
20-6	1586-1597	significant	abstract[99]	giv[99]	_	_
20-7	1598-1610	moisturizing	abstract[99]	giv[99]	_	_
20-8	1611-1617	effect	abstract[99]	giv[99]	_	_
20-9	1618-1623	after	abstract[99]	giv[99]	_	_
20-10	1624-1629	using	abstract[99]	giv[99]	_	_
20-11	1630-1633	the	abstract[99]|substance[100]	giv[99]|new[100]	_	_
20-12	1634-1642	cosmetic	abstract[99]|substance[100]	giv[99]|new[100]	_	_
20-13	1643-1648	under	abstract[99]|substance[100]	giv[99]|new[100]	_	_
20-14	1649-1660	examination	abstract[99]|substance[100]|abstract	giv[99]|new[100]|new	_	_
20-15	1661-1664	and	_	_	_	_
20-16	1665-1667	go	_	_	_	_
20-17	1668-1672	well	_	_	_	_
20-18	1673-1677	with	_	_	_	_
20-19	1678-1681	the	abstract[102]	new[102]	ana	20-41[0_102]
20-20	1682-1691	rationale	abstract[102]	new[102]	_	_
20-21	1692-1694	of	abstract[102]	new[102]	_	_
20-22	1695-1698	the	abstract[102]|substance[103]	new[102]|new[103]	coref	21-8[114_103]
20-23	1699-1710	formulation	abstract[102]|substance[103]	new[102]|new[103]	_	_
20-24	1711-1712	,	abstract[102]	new[102]	_	_
20-25	1713-1718	based	abstract[102]	new[102]	_	_
20-26	1719-1721	on	abstract[102]	new[102]	_	_
20-27	1722-1733	ingredients	abstract[102]|substance[104]	new[102]|new[104]	_	_
20-28	1734-1738	able	abstract[102]|substance[104]	new[102]|new[104]	_	_
20-29	1739-1741	to	abstract[102]|substance[104]	new[102]|new[104]	_	_
20-30	1742-1752	moisturize	abstract[102]|substance[104]	new[102]|new[104]	_	_
20-31	1753-1760	rapidly	abstract[102]|substance[104]	new[102]|new[104]	_	_
20-32	1761-1764	the	abstract[102]|substance[104]|object[105]	new[102]|new[104]|giv[105]	coref	21-11[115_105]
20-33	1765-1769	skin	abstract[102]|substance[104]|object[105]	new[102]|new[104]|giv[105]	_	_
20-34	1770-1773	and	abstract[102]|substance[104]	new[102]|new[104]	_	_
20-35	1774-1781	recover	abstract[102]|substance[104]	new[102]|new[104]	_	_
20-36	1782-1785	the	abstract[102]|substance[104]|object[106]	new[102]|new[104]|giv[106]	coref	23-32[133_106]
20-37	1786-1795	cutaneous	abstract[102]|substance[104]|object[106]	new[102]|new[104]|giv[106]	_	_
20-38	1796-1803	barrier	abstract[102]|substance[104]|object[106]	new[102]|new[104]|giv[106]	_	_
20-39	1804-1806	to	_	_	_	_
20-40	1807-1812	allow	_	_	_	_
20-41	1813-1815	it	abstract	giv	ana	20-49
20-42	1816-1818	to	_	_	_	_
20-43	1819-1825	better	_	_	_	_
20-44	1826-1830	hold	_	_	_	_
20-45	1831-1834	the	substance[108]	giv[108]	coref	23-38[0_108]
20-46	1835-1840	water	substance[108]	giv[108]	_	_
20-47	1841-1848	present	substance[108]	giv[108]	_	_
20-48	1849-1853	into	substance[108]	giv[108]	_	_
20-49	1854-1857	its	substance[108]|abstract|abstract[110]	giv[108]|giv|new[110]	_	_
20-50	1858-1863	outer	substance[108]|abstract[110]	giv[108]|new[110]	_	_
20-51	1864-1870	layers	substance[108]|abstract[110]	giv[108]|new[110]	_	_
20-52	1871-1872	.	_	_	_	_

#Text=In vivo evaluation of the efficacy of a formulation for atopic and very dry skin ( Xerosis ) was done .
21-1	1873-1875	In	_	_	_	_
21-2	1876-1880	vivo	abstract|event[112]	new|new[112]	_	_
21-3	1881-1891	evaluation	event[112]	new[112]	_	_
21-4	1892-1894	of	event[112]	new[112]	_	_
21-5	1895-1898	the	event[112]|abstract[113]	new[112]|new[113]	_	_
21-6	1899-1907	efficacy	event[112]|abstract[113]	new[112]|new[113]	_	_
21-7	1908-1910	of	event[112]|abstract[113]	new[112]|new[113]	_	_
21-8	1911-1912	a	event[112]|abstract[113]|substance[114]	new[112]|new[113]|giv[114]	coref	22-4[118_114]
21-9	1913-1924	formulation	event[112]|abstract[113]|substance[114]	new[112]|new[113]|giv[114]	_	_
21-10	1925-1928	for	event[112]|abstract[113]|substance[114]	new[112]|new[113]|giv[114]	_	_
21-11	1929-1935	atopic	event[112]|abstract[113]|substance[114]|object[115]	new[112]|new[113]|giv[114]|giv[115]	coref	28-42[188_115]
21-12	1936-1939	and	event[112]|abstract[113]|substance[114]|object[115]	new[112]|new[113]|giv[114]|giv[115]	_	_
21-13	1940-1944	very	event[112]|abstract[113]|substance[114]|object[115]	new[112]|new[113]|giv[114]|giv[115]	_	_
21-14	1945-1948	dry	event[112]|abstract[113]|substance[114]|object[115]	new[112]|new[113]|giv[114]|giv[115]	_	_
21-15	1949-1953	skin	event[112]|abstract[113]|substance[114]|object[115]	new[112]|new[113]|giv[114]|giv[115]	_	_
21-16	1954-1955	(	_	_	_	_
21-17	1956-1963	Xerosis	abstract	new	coref	23-44[138_0]
21-18	1964-1965	)	_	_	_	_
21-19	1966-1969	was	_	_	_	_
21-20	1970-1974	done	_	_	_	_
21-21	1975-1976	.	_	_	_	_

#Text=An example of one topical formulation for atopic dermatitis ( Table 1 ) based on trehalose and ceramides based ingredient is reported below for illustrative and non-limiting purposes .
22-1	1977-1979	An	abstract[117]	new[117]	_	_
22-2	1980-1987	example	abstract[117]	new[117]	_	_
22-3	1988-1990	of	abstract[117]	new[117]	_	_
22-4	1991-1994	one	abstract[117]|substance[118]	new[117]|giv[118]	coref	24-4[144_118]
22-5	1995-2002	topical	abstract[117]|substance[118]	new[117]|giv[118]	_	_
22-6	2003-2014	formulation	abstract[117]|substance[118]	new[117]|giv[118]	_	_
22-7	2015-2018	for	abstract[117]|substance[118]	new[117]|giv[118]	_	_
22-8	2019-2025	atopic	abstract[117]|substance[118]|abstract[119]	new[117]|giv[118]|new[119]	coref	23-23[131_119]
22-9	2026-2036	dermatitis	abstract[117]|substance[118]|abstract[119]	new[117]|giv[118]|new[119]	_	_
22-10	2037-2038	(	abstract[117]	new[117]	_	_
22-11	2039-2044	Table	abstract[117]|abstract[120]	new[117]|new[120]	_	_
22-12	2045-2046	1	abstract[117]|abstract[120]	new[117]|new[120]	_	_
22-13	2047-2048	)	abstract[117]	new[117]	_	_
22-14	2049-2054	based	abstract[117]	new[117]	_	_
22-15	2055-2057	on	abstract[117]	new[117]	_	_
22-16	2058-2067	trehalose	abstract[117]|substance|substance[123]	new[117]|giv|giv[123]	coref|coref	24-9|28-9[179_123]
22-17	2068-2071	and	abstract[117]|substance[123]	new[117]|giv[123]	_	_
22-18	2072-2081	ceramides	abstract[117]|substance|substance[123]	new[117]|giv|giv[123]	coref	24-11
22-19	2082-2087	based	abstract[117]|substance[123]	new[117]|giv[123]	_	_
22-20	2088-2098	ingredient	abstract[117]|substance[123]	new[117]|giv[123]	_	_
22-21	2099-2101	is	_	_	_	_
22-22	2102-2110	reported	_	_	_	_
22-23	2111-2116	below	_	_	_	_
22-24	2117-2120	for	_	_	_	_
22-25	2121-2133	illustrative	abstract[124]	new[124]	_	_
22-26	2134-2137	and	abstract[124]	new[124]	_	_
22-27	2138-2150	non-limiting	abstract[124]	new[124]	_	_
22-28	2151-2159	purposes	abstract[124]	new[124]	_	_
22-29	2160-2161	.	_	_	_	_

#Text=Purpose of the test : To provide active substances through a form that allows a prompt release and an effective amount in atopic dermatitis , characterized by a deteriorated functionality of the barrier , an increased transepidermal water loss ( TEWL ) and a significant xerosis , as well as in the case of pathologies associated with a local subcutaneous microcirculation disorder .
23-1	2162-2169	Purpose	abstract[125]	new[125]	_	_
23-2	2170-2172	of	abstract[125]	new[125]	_	_
23-3	2173-2176	the	abstract[125]|abstract[126]	new[125]|new[126]	coref	26-5[156_126]
23-4	2177-2181	test	abstract[125]|abstract[126]	new[125]|new[126]	_	_
23-5	2182-2183	:	_	_	_	_
23-6	2184-2186	To	_	_	_	_
23-7	2187-2194	provide	_	_	_	_
23-8	2195-2201	active	substance[127]	new[127]	_	_
23-9	2202-2212	substances	substance[127]	new[127]	_	_
23-10	2213-2220	through	_	_	_	_
23-11	2221-2222	a	abstract[128]	new[128]	_	_
23-12	2223-2227	form	abstract[128]	new[128]	_	_
23-13	2228-2232	that	abstract[128]	new[128]	_	_
23-14	2233-2239	allows	abstract[128]	new[128]	_	_
23-15	2240-2241	a	abstract[128]|event[129]	new[128]|new[129]	_	_
23-16	2242-2248	prompt	abstract[128]|event[129]	new[128]|new[129]	_	_
23-17	2249-2256	release	abstract[128]|event[129]	new[128]|new[129]	_	_
23-18	2257-2260	and	abstract[128]	new[128]	_	_
23-19	2261-2263	an	abstract[128]|substance[130]	new[128]|giv[130]	_	_
23-20	2264-2273	effective	abstract[128]|substance[130]	new[128]|giv[130]	_	_
23-21	2274-2280	amount	abstract[128]|substance[130]	new[128]|giv[130]	_	_
23-22	2281-2283	in	abstract[128]|substance[130]	new[128]|giv[130]	_	_
23-23	2284-2290	atopic	abstract[128]|substance[130]|abstract[131]	new[128]|giv[130]|giv[131]	_	_
23-24	2291-2301	dermatitis	abstract[128]|substance[130]|abstract[131]	new[128]|giv[130]|giv[131]	_	_
23-25	2302-2303	,	abstract[128]|substance[130]|abstract[131]	new[128]|giv[130]|giv[131]	_	_
23-26	2304-2317	characterized	abstract[128]|substance[130]|abstract[131]	new[128]|giv[130]|giv[131]	_	_
23-27	2318-2320	by	abstract[128]|substance[130]|abstract[131]	new[128]|giv[130]|giv[131]	_	_
23-28	2321-2322	a	abstract[128]|substance[130]|abstract[131]|abstract[132]	new[128]|giv[130]|giv[131]|new[132]	_	_
23-29	2323-2335	deteriorated	abstract[128]|substance[130]|abstract[131]|abstract[132]	new[128]|giv[130]|giv[131]|new[132]	_	_
23-30	2336-2349	functionality	abstract[128]|substance[130]|abstract[131]|abstract[132]	new[128]|giv[130]|giv[131]|new[132]	_	_
23-31	2350-2352	of	abstract[128]|substance[130]|abstract[131]|abstract[132]	new[128]|giv[130]|giv[131]|new[132]	_	_
23-32	2353-2356	the	abstract[128]|substance[130]|abstract[131]|abstract[132]|object[133]	new[128]|giv[130]|giv[131]|new[132]|giv[133]	_	_
23-33	2357-2364	barrier	abstract[128]|substance[130]|abstract[131]|abstract[132]|object[133]	new[128]|giv[130]|giv[131]|new[132]|giv[133]	_	_
23-34	2365-2366	,	abstract[128]|substance[130]|abstract[131]	new[128]|giv[130]|giv[131]	_	_
23-35	2367-2369	an	abstract[128]|substance[130]|abstract[131]|abstract[136]	new[128]|giv[130]|giv[131]|giv[136]	coref	37-7[258_136]
23-36	2370-2379	increased	abstract[128]|substance[130]|abstract[131]|abstract[136]	new[128]|giv[130]|giv[131]|giv[136]	_	_
23-37	2380-2394	transepidermal	abstract[128]|substance[130]|abstract[131]|place|abstract[136]	new[128]|giv[130]|giv[131]|giv|giv[136]	_	_
23-38	2395-2400	water	abstract[128]|substance[130]|abstract[131]|substance|abstract[136]	new[128]|giv[130]|giv[131]|giv|giv[136]	coref	37-8
23-39	2401-2405	loss	abstract[128]|substance[130]|abstract[131]|abstract[136]	new[128]|giv[130]|giv[131]|giv[136]	_	_
23-40	2406-2407	(	abstract[128]|substance[130]|abstract[131]	new[128]|giv[130]|giv[131]	_	_
23-41	2408-2412	TEWL	abstract[128]|substance[130]|abstract[131]|abstract	new[128]|giv[130]|giv[131]|giv	coref	35-18
23-42	2413-2414	)	abstract[128]|substance[130]|abstract[131]	new[128]|giv[130]|giv[131]	_	_
23-43	2415-2418	and	abstract[128]|substance[130]|abstract[131]	new[128]|giv[130]|giv[131]	_	_
23-44	2419-2420	a	abstract[128]|substance[130]|abstract[131]|abstract[138]	new[128]|giv[130]|giv[131]|giv[138]	coref	28-48[0_138]
23-45	2421-2432	significant	abstract[128]|substance[130]|abstract[131]|abstract[138]	new[128]|giv[130]|giv[131]|giv[138]	_	_
23-46	2433-2440	xerosis	abstract[128]|substance[130]|abstract[131]|abstract[138]	new[128]|giv[130]|giv[131]|giv[138]	_	_
23-47	2441-2442	,	_	_	_	_
23-48	2443-2445	as	_	_	_	_
23-49	2446-2450	well	_	_	_	_
23-50	2451-2453	as	_	_	_	_
23-51	2454-2456	in	_	_	_	_
23-52	2457-2460	the	abstract[139]	new[139]	_	_
23-53	2461-2465	case	abstract[139]	new[139]	_	_
23-54	2466-2468	of	abstract[139]	new[139]	_	_
23-55	2469-2480	pathologies	abstract[139]|abstract[140]	new[139]|new[140]	_	_
23-56	2481-2491	associated	abstract[139]|abstract[140]	new[139]|new[140]	_	_
23-57	2492-2496	with	abstract[139]|abstract[140]	new[139]|new[140]	_	_
23-58	2497-2498	a	abstract[139]|abstract[140]|abstract[142]	new[139]|new[140]|new[142]	_	_
23-59	2499-2504	local	abstract[139]|abstract[140]|abstract[142]	new[139]|new[140]|new[142]	_	_
23-60	2505-2517	subcutaneous	abstract[139]|abstract[140]|abstract[142]	new[139]|new[140]|new[142]	_	_
23-61	2518-2534	microcirculation	abstract[139]|abstract[140]|substance|abstract[142]	new[139]|new[140]|new|new[142]	_	_
23-62	2535-2543	disorder	abstract[139]|abstract[140]|abstract[142]	new[139]|new[140]|new[142]	_	_
23-63	2544-2545	.	_	_	_	_

#Text=The efficacy of a topical cosmetic formulation containing trehalose and ceramides in comparison to a placebo has been evaluated .
24-1	2546-2549	The	abstract[143]	new[143]	_	_
24-2	2550-2558	efficacy	abstract[143]	new[143]	_	_
24-3	2559-2561	of	abstract[143]	new[143]	_	_
24-4	2562-2563	a	abstract[143]|substance[144]	new[143]|giv[144]	_	_
24-5	2564-2571	topical	abstract[143]|substance[144]	new[143]|giv[144]	_	_
24-6	2572-2580	cosmetic	abstract[143]|substance[144]	new[143]|giv[144]	_	_
24-7	2581-2592	formulation	abstract[143]|substance[144]	new[143]|giv[144]	_	_
24-8	2593-2603	containing	abstract[143]|substance[144]	new[143]|giv[144]	_	_
24-9	2604-2613	trehalose	abstract[143]|substance[144]|substance	new[143]|giv[144]|giv	coref	28-9
24-10	2614-2617	and	abstract[143]|substance[144]	new[143]|giv[144]	_	_
24-11	2618-2627	ceramides	abstract[143]|substance[144]|substance	new[143]|giv[144]|giv	coref	28-11
24-12	2628-2630	in	abstract[143]|substance[144]	new[143]|giv[144]	_	_
24-13	2631-2641	comparison	abstract[143]|substance[144]	new[143]|giv[144]	_	_
24-14	2642-2644	to	abstract[143]|substance[144]	new[143]|giv[144]	_	_
24-15	2645-2646	a	abstract[143]|substance[144]|person[147]	new[143]|giv[144]|giv[147]	coref	28-14[180_147]
24-16	2647-2654	placebo	abstract[143]|substance[144]|person[147]	new[143]|giv[144]|giv[147]	_	_
24-17	2655-2658	has	_	_	_	_
24-18	2659-2663	been	_	_	_	_
24-19	2664-2673	evaluated	_	_	_	_
24-20	2674-2675	.	_	_	_	_

#Text=Mean values , standard deviations , and variations were calculated for each set of values .
25-1	2676-2680	Mean	person|abstract[149]	new|new[149]	coref	25-15[0_149]
25-2	2681-2687	values	abstract[149]	new[149]	_	_
25-3	2688-2689	,	_	_	_	_
25-4	2690-2698	standard	abstract[150]	new[150]	_	_
25-5	2699-2709	deviations	abstract[150]	new[150]	_	_
25-6	2710-2711	,	_	_	_	_
25-7	2712-2715	and	_	_	_	_
25-8	2716-2726	variations	abstract	new	coref	26-24[162_0]
25-9	2727-2731	were	_	_	_	_
25-10	2732-2742	calculated	_	_	_	_
25-11	2743-2746	for	_	_	_	_
25-12	2747-2751	each	abstract[152]	new[152]	_	_
25-13	2752-2755	set	abstract[152]	new[152]	_	_
25-14	2756-2758	of	abstract[152]	new[152]	_	_
25-15	2759-2765	values	abstract[152]|abstract	new[152]|giv	coref	39-6[269_0]
25-16	2766-2767	.	_	_	_	_

#Text=Following the results of normality test ( Kolmogorov – Smirnov test ) , the instrumental data ( T0 , T4 weeks ) and the variations ( T4 weeks-T0 ) were statistically compared by means of t -test for parametric and dependent data .
26-1	2768-2777	Following	_	_	_	_
26-2	2778-2781	the	abstract[154]	giv[154]	_	_
26-3	2782-2789	results	abstract[154]	giv[154]	_	_
26-4	2790-2792	of	abstract[154]	giv[154]	_	_
26-5	2793-2802	normality	abstract[154]|abstract|abstract[156]	giv[154]|new|giv[156]	coref	30-6[203_156]
26-6	2803-2807	test	abstract[154]|abstract[156]	giv[154]|giv[156]	_	_
26-7	2808-2809	(	_	_	_	_
26-8	2810-2820	Kolmogorov	person	new	_	_
26-9	2821-2822	–	_	_	_	_
26-10	2823-2830	Smirnov	person	new	_	_
26-11	2831-2835	test	_	_	_	_
26-12	2836-2837	)	_	_	_	_
26-13	2838-2839	,	_	_	_	_
26-14	2840-2843	the	abstract[159]	new[159]	appos	26-18[0_159]
26-15	2844-2856	instrumental	abstract[159]	new[159]	_	_
26-16	2857-2861	data	abstract[159]	new[159]	_	_
26-17	2862-2863	(	_	_	_	_
26-18	2864-2866	T0	abstract	giv	coref	26-39[165_0]
26-19	2867-2868	,	_	_	_	_
26-20	2869-2871	T4	time[161]	giv[161]	coref	28-56[191_161]
26-21	2872-2877	weeks	time[161]	giv[161]	_	_
26-22	2878-2879	)	_	_	_	_
26-23	2880-2883	and	_	_	_	_
26-24	2884-2887	the	abstract[162]	giv[162]	_	_
26-25	2888-2898	variations	abstract[162]	giv[162]	_	_
26-26	2899-2900	(	_	_	_	_
26-27	2901-2903	T4	time[163]	new[163]	_	_
26-28	2904-2912	weeks-T0	time[163]	new[163]	_	_
26-29	2913-2914	)	_	_	_	_
26-30	2915-2919	were	_	_	_	_
26-31	2920-2933	statistically	_	_	_	_
26-32	2934-2942	compared	_	_	_	_
26-33	2943-2945	by	_	_	_	_
26-34	2946-2951	means	_	_	_	_
26-35	2952-2954	of	_	_	_	_
26-36	2955-2956	t	abstract	new	_	_
26-37	2957-2962	-test	_	_	_	_
26-38	2963-2966	for	_	_	_	_
26-39	2967-2977	parametric	abstract[165]	giv[165]	coref	27-8[0_165]
26-40	2978-2981	and	abstract[165]	giv[165]	_	_
26-41	2982-2991	dependent	abstract[165]	giv[165]	_	_
26-42	2992-2996	data	abstract[165]	giv[165]	_	_
26-43	2997-2998	.	_	_	_	_

#Text=In all cases , the groups of data were considered statistically different for a probability value p < 0.05 .
27-1	2999-3001	In	_	_	_	_
27-2	3002-3005	all	object[166]	new[166]	_	_
27-3	3006-3011	cases	object[166]	new[166]	_	_
27-4	3012-3013	,	_	_	_	_
27-5	3014-3017	the	person[167]	new[167]	_	_
27-6	3018-3024	groups	person[167]	new[167]	_	_
27-7	3025-3027	of	person[167]	new[167]	_	_
27-8	3028-3032	data	person[167]|abstract	new[167]|giv	_	_
27-9	3033-3037	were	_	_	_	_
27-10	3038-3048	considered	_	_	_	_
27-11	3049-3062	statistically	_	_	_	_
27-12	3063-3072	different	_	_	_	_
27-13	3073-3076	for	_	_	_	_
27-14	3077-3078	a	abstract[170]|abstract[171]	giv[170]|giv[171]	_	_
27-15	3079-3090	probability	abstract|abstract[170]|abstract[171]	new|giv[170]|giv[171]	_	_
27-16	3091-3096	value	abstract[170]|abstract[171]	giv[170]|giv[171]	_	_
27-17	3097-3098	p	abstract[170]|abstract[171]	giv[170]|giv[171]	_	_
27-18	3099-3100	<	abstract[170]|abstract[171]	giv[170]|giv[171]	_	_
27-19	3101-3105	0.05	abstract[170]|abstract[171]|abstract	giv[170]|giv[171]|new	_	_
27-20	3106-3107	.	_	_	_	_

#Text=Protocol of double-blind study : the product containing trehalose and ceramides ingredient and the placebo was applied on the forearms by 20 volunteers of either sex ( 1 male and 19 females with an average age of 50 years ) with atopic and very dry skin ( xerosis ) , twice a day , for 4 weeks .
28-1	3108-3116	Protocol	abstract[173]	new[173]	_	_
28-2	3117-3119	of	abstract[173]	new[173]	_	_
28-3	3120-3132	double-blind	abstract[173]|abstract[174]	new[173]|giv[174]	coref	29-2[192_174]
28-4	3133-3138	study	abstract[173]|abstract[174]	new[173]|giv[174]	_	_
28-5	3139-3140	:	_	_	_	_
28-6	3141-3144	the	substance[175]	giv[175]	coref	32-19[223_175]
28-7	3145-3152	product	substance[175]	giv[175]	_	_
28-8	3153-3163	containing	substance[175]	giv[175]	_	_
28-9	3164-3173	trehalose	substance[175]|substance|substance[177]|substance[179]	giv[175]|giv|new[177]|giv[179]	coref|coref|coref	31-20|31-20[215_177]|31-20[217_179]
28-10	3174-3177	and	substance[175]|substance[177]|substance[179]	giv[175]|new[177]|giv[179]	_	_
28-11	3178-3187	ceramides	substance[175]|substance[177]|substance|substance[179]	giv[175]|new[177]|giv|giv[179]	coref	31-22
28-12	3188-3198	ingredient	substance[175]|substance[177]|substance[179]	giv[175]|new[177]|giv[179]	_	_
28-13	3199-3202	and	substance[175]|substance[177]|substance[179]	giv[175]|new[177]|giv[179]	_	_
28-14	3203-3206	the	substance[175]|substance[177]|substance[179]|person[180]	giv[175]|new[177]|giv[179]|giv[180]	coref	31-26[0_180]
28-15	3207-3214	placebo	substance[175]|substance[177]|substance[179]|person[180]	giv[175]|new[177]|giv[179]|giv[180]	_	_
28-16	3215-3218	was	_	_	_	_
28-17	3219-3226	applied	_	_	_	_
28-18	3227-3229	on	_	_	_	_
28-19	3230-3233	the	object[181]	new[181]	coref	30-19[206_181]
28-20	3234-3242	forearms	object[181]	new[181]	_	_
28-21	3243-3245	by	_	_	_	_
28-22	3246-3248	20	person[182]	new[182]	coref	31-31[219_182]
28-23	3249-3259	volunteers	person[182]	new[182]	_	_
28-24	3260-3262	of	person[182]	new[182]	_	_
28-25	3263-3269	either	person[182]|abstract[183]	new[182]|new[183]	_	_
28-26	3270-3273	sex	person[182]|abstract[183]	new[182]|new[183]	_	_
28-27	3274-3275	(	_	_	_	_
28-28	3276-3277	1	person[184]	new[184]	_	_
28-29	3278-3282	male	person[184]	new[184]	_	_
28-30	3283-3286	and	_	_	_	_
28-31	3287-3289	19	person[185]	new[185]	ana	29-10[0_185]
28-32	3290-3297	females	person[185]	new[185]	_	_
28-33	3298-3302	with	person[185]	new[185]	_	_
28-34	3303-3305	an	person[185]|abstract[186]	new[185]|new[186]	_	_
28-35	3306-3313	average	person[185]|abstract[186]	new[185]|new[186]	_	_
28-36	3314-3317	age	person[185]|abstract[186]	new[185]|new[186]	_	_
28-37	3318-3320	of	person[185]|abstract[186]	new[185]|new[186]	_	_
28-38	3321-3323	50	person[185]|abstract[186]|time[187]	new[185]|new[186]|new[187]	_	_
28-39	3324-3329	years	person[185]|abstract[186]|time[187]	new[185]|new[186]|new[187]	_	_
28-40	3330-3331	)	_	_	_	_
28-41	3332-3336	with	_	_	_	_
28-42	3337-3343	atopic	object[188]	giv[188]	coref	37-4[0_188]
28-43	3344-3347	and	object[188]	giv[188]	_	_
28-44	3348-3352	very	object[188]	giv[188]	_	_
28-45	3353-3356	dry	object[188]	giv[188]	_	_
28-46	3357-3361	skin	object[188]	giv[188]	_	_
28-47	3362-3363	(	_	_	_	_
28-48	3364-3371	xerosis	abstract	giv	_	_
28-49	3372-3373	)	_	_	_	_
28-50	3374-3375	,	_	_	_	_
28-51	3376-3381	twice	_	_	_	_
28-52	3382-3383	a	time[190]	new[190]	coref	33-24[233_190]
28-53	3384-3387	day	time[190]	new[190]	_	_
28-54	3388-3389	,	_	_	_	_
28-55	3390-3393	for	_	_	_	_
28-56	3394-3395	4	time[191]	giv[191]	coref	37-31[264_191]
28-57	3396-3401	weeks	time[191]	giv[191]	_	_
28-58	3402-3403	.	_	_	_	_

#Text=During the study , subjects were instructed to wash their body using their current skin care regimen and to not apply the tested products on any other site than the prescribed ones .
29-1	3404-3410	During	_	_	_	_
29-2	3411-3414	the	abstract[192]	giv[192]	coref	33-21[0_192]
29-3	3415-3420	study	abstract[192]	giv[192]	_	_
29-4	3421-3422	,	_	_	_	_
29-5	3423-3431	subjects	person	new	coref	30-9[204_0]
29-6	3432-3436	were	_	_	_	_
29-7	3437-3447	instructed	_	_	_	_
29-8	3448-3450	to	_	_	_	_
29-9	3451-3455	wash	_	_	_	_
29-10	3456-3461	their	person|object[195]	giv|new[195]	ana	29-13
29-11	3462-3466	body	object[195]	new[195]	_	_
29-12	3467-3472	using	_	_	_	_
29-13	3473-3478	their	person|abstract[198]	giv|new[198]	_	_
29-14	3479-3486	current	abstract[198]	new[198]	_	_
29-15	3487-3491	skin	abstract[197]|abstract[198]	new[197]|new[198]	_	_
29-16	3492-3496	care	abstract[197]|abstract[198]	new[197]|new[198]	_	_
29-17	3497-3504	regimen	abstract[198]	new[198]	_	_
29-18	3505-3508	and	_	_	_	_
29-19	3509-3511	to	_	_	_	_
29-20	3512-3515	not	_	_	_	_
29-21	3516-3521	apply	_	_	_	_
29-22	3522-3525	the	object[199]	new[199]	coref	30-16[205_199]
29-23	3526-3532	tested	object[199]	new[199]	_	_
29-24	3533-3541	products	object[199]	new[199]	_	_
29-25	3542-3544	on	_	_	_	_
29-26	3545-3548	any	place[200]	giv[200]	_	_
29-27	3549-3554	other	place[200]	giv[200]	_	_
29-28	3555-3559	site	place[200]	giv[200]	_	_
29-29	3560-3564	than	place[200]	giv[200]	_	_
29-30	3565-3568	the	place[200]|object[201]	giv[200]|new[201]	_	_
29-31	3569-3579	prescribed	place[200]|object[201]	giv[200]|new[201]	_	_
29-32	3580-3584	ones	place[200]|object[201]	giv[200]|new[201]	_	_
29-33	3585-3586	.	_	_	_	_

#Text=For the whole duration of the test , the subjects were not allowed to use different products on the forearms and instructed to avoid UV exposure .
30-1	3587-3590	For	_	_	_	_
30-2	3591-3594	the	time[202]	new[202]	_	_
30-3	3595-3600	whole	time[202]	new[202]	_	_
30-4	3601-3609	duration	time[202]	new[202]	_	_
30-5	3610-3612	of	time[202]	new[202]	_	_
30-6	3613-3616	the	time[202]|abstract[203]	new[202]|giv[203]	_	_
30-7	3617-3621	test	time[202]|abstract[203]	new[202]|giv[203]	_	_
30-8	3622-3623	,	_	_	_	_
30-9	3624-3627	the	person[204]	giv[204]	coref	34-6[235_204]
30-10	3628-3636	subjects	person[204]	giv[204]	_	_
30-11	3637-3641	were	_	_	_	_
30-12	3642-3645	not	_	_	_	_
30-13	3646-3653	allowed	_	_	_	_
30-14	3654-3656	to	_	_	_	_
30-15	3657-3660	use	_	_	_	_
30-16	3661-3670	different	object[205]	giv[205]	coref	34-1[234_205]
30-17	3671-3679	products	object[205]	giv[205]	_	_
30-18	3680-3682	on	_	_	_	_
30-19	3683-3686	the	object[206]	giv[206]	coref	37-24[262_206]
30-20	3687-3695	forearms	object[206]	giv[206]	_	_
30-21	3696-3699	and	_	_	_	_
30-22	3700-3710	instructed	_	_	_	_
30-23	3711-3713	to	_	_	_	_
30-24	3714-3719	avoid	_	_	_	_
30-25	3720-3722	UV	substance|abstract[208]	new|new[208]	_	_
30-26	3723-3731	exposure	abstract[208]	new[208]	_	_
30-27	3732-3733	.	_	_	_	_

#Text=Furthermore , the side of application ( left or right forearm ) of the two formulations ( cream containing trehalose and ceramides based ingredient and placebo ) were randomized among the volunteers .
31-1	3734-3745	Furthermore	_	_	_	_
31-2	3746-3747	,	_	_	_	_
31-3	3748-3751	the	object[209]	new[209]	_	_
31-4	3752-3756	side	object[209]	new[209]	_	_
31-5	3757-3759	of	object[209]	new[209]	_	_
31-6	3760-3771	application	object[209]|event	new[209]|giv	_	_
31-7	3772-3773	(	_	_	_	_
31-8	3774-3778	left	object[211]	new[211]	_	_
31-9	3779-3781	or	object[211]	new[211]	_	_
31-10	3782-3787	right	object[211]	new[211]	_	_
31-11	3788-3795	forearm	object[211]	new[211]	_	_
31-12	3796-3797	)	_	_	_	_
31-13	3798-3800	of	_	_	_	_
31-14	3801-3804	the	substance[212]	new[212]	appos	31-18[213_212]
31-15	3805-3808	two	substance[212]	new[212]	_	_
31-16	3809-3821	formulations	substance[212]	new[212]	_	_
31-17	3822-3823	(	_	_	_	_
31-18	3824-3829	cream	substance[213]	giv[213]	coref	39-21[278_213]
31-19	3830-3840	containing	substance[213]	giv[213]	_	_
31-20	3841-3850	trehalose	substance[213]|substance|substance[215]|substance[217]	giv[213]|giv|giv[215]|giv[217]	coref|coref	35-8[241_217]|39-25
31-21	3851-3854	and	substance[213]|substance[215]|substance[217]	giv[213]|giv[215]|giv[217]	_	_
31-22	3855-3864	ceramides	substance[213]|substance[215]|substance|substance[217]	giv[213]|giv[215]|giv|giv[217]	coref	39-23
31-23	3865-3870	based	substance[213]|substance[215]|substance[217]	giv[213]|giv[215]|giv[217]	_	_
31-24	3871-3881	ingredient	substance[213]|substance[215]|substance[217]	giv[213]|giv[215]|giv[217]	_	_
31-25	3882-3885	and	substance[213]|substance[215]|substance[217]	giv[213]|giv[215]|giv[217]	_	_
31-26	3886-3893	placebo	substance[213]|substance[215]|substance[217]|person	giv[213]|giv[215]|giv[217]|giv	coref	35-11
31-27	3894-3895	)	_	_	_	_
31-28	3896-3900	were	_	_	_	_
31-29	3901-3911	randomized	_	_	_	_
31-30	3912-3917	among	_	_	_	_
31-31	3918-3921	the	person[219]	giv[219]	_	_
31-32	3922-3932	volunteers	person[219]	giv[219]	_	_
31-33	3933-3934	.	_	_	_	_

#Text=Each sample was labeled “ right ” or “ left ” , indicating the side of application of the product .
32-1	3935-3939	Each	object[220]	new[220]	_	_
32-2	3940-3946	sample	object[220]	new[220]	_	_
32-3	3947-3950	was	_	_	_	_
32-4	3951-3958	labeled	_	_	_	_
32-5	3959-3960	“	_	_	_	_
32-6	3961-3966	right	_	_	_	_
32-7	3967-3968	”	_	_	_	_
32-8	3969-3971	or	_	_	_	_
32-9	3972-3973	“	_	_	_	_
32-10	3974-3978	left	_	_	_	_
32-11	3979-3980	”	_	_	_	_
32-12	3981-3982	,	_	_	_	_
32-13	3983-3993	indicating	_	_	_	_
32-14	3994-3997	the	abstract[221]	new[221]	_	_
32-15	3998-4002	side	abstract[221]	new[221]	_	_
32-16	4003-4005	of	abstract[221]	new[221]	_	_
32-17	4006-4017	application	abstract[221]|abstract[222]	new[221]|new[222]	_	_
32-18	4018-4020	of	abstract[221]|abstract[222]	new[221]|new[222]	_	_
32-19	4021-4024	the	abstract[221]|abstract[222]|substance[223]	new[221]|new[222]|giv[223]	coref	39-30[280_223]
32-20	4025-4032	product	abstract[221]|abstract[222]|substance[223]	new[221]|new[222]|giv[223]	_	_
32-21	4033-4034	.	_	_	_	_

#Text=The assignment of subject number and subsequent placement on the randomization chart were made in order of appearance at the study center on the first day .
33-1	4035-4038	The	abstract[224]	new[224]	_	_
33-2	4039-4049	assignment	abstract[224]	new[224]	_	_
33-3	4050-4052	of	abstract[224]	new[224]	_	_
33-4	4053-4060	subject	abstract[224]|abstract|abstract[226]	new[224]|new|new[226]	_	_
33-5	4061-4067	number	abstract[224]|abstract[226]	new[224]|new[226]	_	_
33-6	4068-4071	and	_	_	_	_
33-7	4072-4082	subsequent	abstract[227]	new[227]	_	_
33-8	4083-4092	placement	abstract[227]	new[227]	_	_
33-9	4093-4095	on	abstract[227]	new[227]	_	_
33-10	4096-4099	the	abstract[227]|abstract[229]	new[227]|new[229]	_	_
33-11	4100-4113	randomization	abstract[227]|abstract|abstract[229]	new[227]|new|new[229]	_	_
33-12	4114-4119	chart	abstract[227]|abstract[229]	new[227]|new[229]	_	_
33-13	4120-4124	were	_	_	_	_
33-14	4125-4129	made	_	_	_	_
33-15	4130-4132	in	_	_	_	_
33-16	4133-4138	order	_	_	_	_
33-17	4139-4141	of	_	_	_	_
33-18	4142-4152	appearance	abstract[230]	new[230]	_	_
33-19	4153-4155	at	abstract[230]	new[230]	_	_
33-20	4156-4159	the	abstract[230]|place[232]	new[230]|new[232]	_	_
33-21	4160-4165	study	abstract[230]|abstract|place[232]	new[230]|giv|new[232]	_	_
33-22	4166-4172	center	abstract[230]|place[232]	new[230]|new[232]	_	_
33-23	4173-4175	on	_	_	_	_
33-24	4176-4179	the	time[233]	giv[233]	_	_
33-25	4180-4185	first	time[233]	giv[233]	_	_
33-26	4186-4189	day	time[233]	giv[233]	_	_
33-27	4190-4191	.	_	_	_	_

#Text=The products were given to the subjects in anonymous containers which did not provide any information about the treatment .
34-1	4192-4195	The	object[234]	giv[234]	_	_
34-2	4196-4204	products	object[234]	giv[234]	_	_
34-3	4205-4209	were	_	_	_	_
34-4	4210-4215	given	_	_	_	_
34-5	4216-4218	to	_	_	_	_
34-6	4219-4222	the	person[235]	giv[235]	_	_
34-7	4223-4231	subjects	person[235]	giv[235]	_	_
34-8	4232-4234	in	_	_	_	_
34-9	4235-4244	anonymous	object[236]	new[236]	_	_
34-10	4245-4255	containers	object[236]	new[236]	_	_
34-11	4256-4261	which	object[236]	new[236]	_	_
34-12	4262-4265	did	object[236]	new[236]	_	_
34-13	4266-4269	not	object[236]	new[236]	_	_
34-14	4270-4277	provide	object[236]	new[236]	_	_
34-15	4278-4281	any	object[236]|abstract[237]	new[236]|new[237]	_	_
34-16	4282-4293	information	object[236]|abstract[237]	new[236]|new[237]	_	_
34-17	4294-4299	about	object[236]|abstract[237]	new[236]|new[237]	_	_
34-18	4300-4303	the	object[236]|abstract[237]|event[238]	new[236]|new[237]|new[238]	coref	37-34[0_238]
34-19	4304-4313	treatment	object[236]|abstract[237]|event[238]	new[236]|new[237]|new[238]	_	_
34-20	4314-4315	.	_	_	_	_

#Text=The comparisons evidenced statistically significant differences between studied ingredient and placebo for both parameters ( hydration and TEWL ) .
35-1	4316-4319	The	abstract[239]	new[239]	_	_
35-2	4320-4331	comparisons	abstract[239]	new[239]	_	_
35-3	4332-4341	evidenced	_	_	_	_
35-4	4342-4355	statistically	abstract[240]	new[240]	_	_
35-5	4356-4367	significant	abstract[240]	new[240]	_	_
35-6	4368-4379	differences	abstract[240]	new[240]	_	_
35-7	4380-4387	between	abstract[240]	new[240]	_	_
35-8	4388-4395	studied	abstract[240]|substance[241]	new[240]|giv[241]	coref	39-27[0_241]
35-9	4396-4406	ingredient	abstract[240]|substance[241]	new[240]|giv[241]	_	_
35-10	4407-4410	and	abstract[240]	new[240]	_	_
35-11	4411-4418	placebo	abstract[240]|person	new[240]|giv	coref	36-20
35-12	4419-4422	for	abstract[240]	new[240]	_	_
35-13	4423-4427	both	abstract[240]|abstract[243]	new[240]|new[243]	appos	35-16[0_243]
35-14	4428-4438	parameters	abstract[240]|abstract[243]	new[240]|new[243]	_	_
35-15	4439-4440	(	_	_	_	_
35-16	4441-4450	hydration	abstract|abstract[245]	giv|giv[245]	appos|coref	35-16[245_0]|37-4[256_245]
35-17	4451-4454	and	abstract[245]	giv[245]	_	_
35-18	4455-4459	TEWL	abstract[245]|abstract	giv[245]|giv	ana	36-1
35-19	4460-4461	)	_	_	_	_
35-20	4462-4463	.	_	_	_	_

#Text=This means that the improvements observed in the active area were statistically higher than the improvements observed in the placebo area .
36-1	4464-4468	This	abstract	giv	coref	37-11
36-2	4469-4474	means	_	_	_	_
36-3	4475-4479	that	_	_	_	_
36-4	4480-4483	the	abstract[248]	new[248]	_	_
36-5	4484-4496	improvements	abstract[248]	new[248]	_	_
36-6	4497-4505	observed	abstract[248]	new[248]	_	_
36-7	4506-4508	in	abstract[248]	new[248]	_	_
36-8	4509-4512	the	abstract[248]|place[249]	new[248]|new[249]	coref	36-19[252_249]
36-9	4513-4519	active	abstract[248]|place[249]	new[248]|new[249]	_	_
36-10	4520-4524	area	abstract[248]|place[249]	new[248]|new[249]	_	_
36-11	4525-4529	were	_	_	_	_
36-12	4530-4543	statistically	_	_	_	_
36-13	4544-4550	higher	_	_	_	_
36-14	4551-4555	than	_	_	_	_
36-15	4556-4559	the	abstract[250]	new[250]	_	_
36-16	4560-4572	improvements	abstract[250]	new[250]	_	_
36-17	4573-4581	observed	abstract[250]	new[250]	_	_
36-18	4582-4584	in	abstract[250]	new[250]	_	_
36-19	4585-4588	the	abstract[250]|place[252]	new[250]|giv[252]	coref	37-16[260_252]
36-20	4589-4596	placebo	abstract[250]|person|place[252]	new[250]|giv|giv[252]	coref	39-31
36-21	4597-4601	area	abstract[250]|place[252]	new[250]|giv[252]	_	_
36-22	4602-4603	.	_	_	_	_

#Text=Instrumental measurements of skin hydration and transepidermal water loss ( TEWL ) were performed on a selected area ( 9 cm2 ) of the forearms at the baseline and after 4 weeks of treatment .
37-1	4604-4616	Instrumental	abstract[253]	new[253]	_	_
37-2	4617-4629	measurements	abstract[253]	new[253]	_	_
37-3	4630-4632	of	abstract[253]	new[253]	_	_
37-4	4633-4637	skin	abstract[253]|object|abstract[255]|abstract[256]	new[253]|giv|giv[255]|giv[256]	coref|coref	38-1[267_255]|39-11
37-5	4638-4647	hydration	abstract[253]|abstract[255]|abstract[256]	new[253]|giv[255]|giv[256]	_	_
37-6	4648-4651	and	abstract[253]|abstract[256]	new[253]|giv[256]	_	_
37-7	4652-4666	transepidermal	abstract[253]|abstract[256]|abstract[258]	new[253]|giv[256]|giv[258]	coref	44-1[299_258]
37-8	4667-4672	water	abstract[253]|abstract[256]|substance|abstract[258]	new[253]|giv[256]|giv|giv[258]	_	_
37-9	4673-4677	loss	abstract[253]|abstract[256]|abstract[258]	new[253]|giv[256]|giv[258]	_	_
37-10	4678-4679	(	_	_	_	_
37-11	4680-4684	TEWL	abstract	giv	coref	44-5
37-12	4685-4686	)	_	_	_	_
37-13	4687-4691	were	_	_	_	_
37-14	4692-4701	performed	_	_	_	_
37-15	4702-4704	on	_	_	_	_
37-16	4705-4706	a	place[260]	giv[260]	_	_
37-17	4707-4715	selected	place[260]	giv[260]	_	_
37-18	4716-4720	area	place[260]	giv[260]	_	_
37-19	4721-4722	(	_	_	_	_
37-20	4723-4724	9	abstract[261]	new[261]	_	_
37-21	4725-4728	cm2	abstract[261]	new[261]	_	_
37-22	4729-4730	)	_	_	_	_
37-23	4731-4733	of	_	_	_	_
37-24	4734-4737	the	object[262]	giv[262]	_	_
37-25	4738-4746	forearms	object[262]	giv[262]	_	_
37-26	4747-4749	at	_	_	_	_
37-27	4750-4753	the	abstract[263]	new[263]	_	_
37-28	4754-4762	baseline	abstract[263]	new[263]	_	_
37-29	4763-4766	and	_	_	_	_
37-30	4767-4772	after	_	_	_	_
37-31	4773-4774	4	time[264]	giv[264]	coref	40-18[289_264]
37-32	4775-4780	weeks	time[264]	giv[264]	_	_
37-33	4781-4783	of	time[264]	giv[264]	_	_
37-34	4784-4793	treatment	time[264]|event	giv[264]|giv	coref	40-21
37-35	4794-4795	.	_	_	_	_

#Text=Skin Hydration
38-1	4796-4800	Skin	person|abstract[267]	new|giv[267]	coref	39-11[271_267]
38-2	4801-4810	Hydration	abstract[267]	giv[267]	_	_

#Text=A statistically significant increase in the mean basal values of skin hydration was evidenced after 4 weeks of application of both the ceramides and trehalose based ingredient cream and the placebo product ( Table 2 ) .
39-1	4811-4812	A	event[268]	new[268]	_	_
39-2	4813-4826	statistically	event[268]	new[268]	_	_
39-3	4827-4838	significant	event[268]	new[268]	_	_
39-4	4839-4847	increase	event[268]	new[268]	_	_
39-5	4848-4850	in	event[268]	new[268]	_	_
39-6	4851-4854	the	event[268]|abstract[269]	new[268]|giv[269]	_	_
39-7	4855-4859	mean	event[268]|abstract[269]	new[268]|giv[269]	_	_
39-8	4860-4865	basal	event[268]|abstract[269]	new[268]|giv[269]	_	_
39-9	4866-4872	values	event[268]|abstract[269]	new[268]|giv[269]	_	_
39-10	4873-4875	of	event[268]|abstract[269]	new[268]|giv[269]	_	_
39-11	4876-4880	skin	event[268]|abstract[269]|object|abstract[271]	new[268]|giv[269]|giv|giv[271]	coref|coref	43-13|43-13[297_271]
39-12	4881-4890	hydration	event[268]|abstract[269]|abstract[271]	new[268]|giv[269]|giv[271]	_	_
39-13	4891-4894	was	_	_	_	_
39-14	4895-4904	evidenced	_	_	_	_
39-15	4905-4910	after	_	_	_	_
39-16	4911-4912	4	time[272]	new[272]	_	_
39-17	4913-4918	weeks	time[272]	new[272]	_	_
39-18	4919-4921	of	time[272]	new[272]	_	_
39-19	4922-4933	application	time[272]|event[273]	new[272]|new[273]	_	_
39-20	4934-4936	of	time[272]|event[273]	new[272]|new[273]	_	_
39-21	4937-4941	both	time[272]|event[273]|substance[277]|substance[278]	new[272]|new[273]|new[277]|giv[278]	coref	40-8[286_277]
39-22	4942-4945	the	time[272]|event[273]|substance[277]|substance[278]	new[272]|new[273]|new[277]|giv[278]	_	_
39-23	4946-4955	ceramides	time[272]|event[273]|substance|substance[277]|substance[278]	new[272]|new[273]|giv|new[277]|giv[278]	coref	40-6
39-24	4956-4959	and	time[272]|event[273]|substance[277]|substance[278]	new[272]|new[273]|new[277]|giv[278]	_	_
39-25	4960-4969	trehalose	time[272]|event[273]|substance|substance[277]|substance[278]	new[272]|new[273]|giv|new[277]|giv[278]	coref	40-8
39-26	4970-4975	based	time[272]|event[273]|substance[277]|substance[278]	new[272]|new[273]|new[277]|giv[278]	_	_
39-27	4976-4986	ingredient	time[272]|event[273]|substance|substance[277]|substance[278]	new[272]|new[273]|giv|new[277]|giv[278]	coref	40-10
39-28	4987-4992	cream	time[272]|event[273]|substance[277]|substance[278]	new[272]|new[273]|new[277]|giv[278]	_	_
39-29	4993-4996	and	time[272]|event[273]|substance[278]	new[272]|new[273]|giv[278]	_	_
39-30	4997-5000	the	time[272]|event[273]|substance[278]|substance[280]	new[272]|new[273]|giv[278]|giv[280]	coref	40-13[288_280]
39-31	5001-5008	placebo	time[272]|event[273]|substance[278]|person|substance[280]	new[272]|new[273]|giv[278]|giv|giv[280]	coref	40-13
39-32	5009-5016	product	time[272]|event[273]|substance[278]|substance[280]	new[272]|new[273]|giv[278]|giv[280]	_	_
39-33	5017-5018	(	_	_	_	_
39-34	5019-5024	Table	_	_	_	_
39-35	5025-5026	2	_	_	_	_
39-36	5027-5028	)	_	_	_	_
39-37	5029-5030	.	_	_	_	_

#Text=A statistically significant difference between ceramides and trehalose based ingredient cream and placebo product was detected after 4 weeks of treatment (
40-1	5031-5032	A	abstract[281]	new[281]	_	_
40-2	5033-5046	statistically	abstract[281]	new[281]	_	_
40-3	5047-5058	significant	abstract[281]	new[281]	_	_
40-4	5059-5069	difference	abstract[281]	new[281]	_	_
40-5	5070-5077	between	abstract[281]	new[281]	_	_
40-6	5078-5087	ceramides	abstract[281]|substance|substance[283]	new[281]|giv|giv[283]	coref|coref	40-6[283_0]|43-6[0_283]
40-7	5088-5091	and	abstract[281]|substance[283]	new[281]|giv[283]	_	_
40-8	5092-5101	trehalose	abstract[281]|substance[283]|substance|substance[286]	new[281]|giv[283]|giv|giv[286]	coref|coref	43-1[292_286]|43-4
40-9	5102-5107	based	abstract[281]|substance[283]|substance[286]	new[281]|giv[283]|giv[286]	_	_
40-10	5108-5118	ingredient	abstract[281]|substance[283]|substance|substance[286]	new[281]|giv[283]|giv|giv[286]	coref	43-6[295_0]
40-11	5119-5124	cream	abstract[281]|substance[283]|substance[286]	new[281]|giv[283]|giv[286]	_	_
40-12	5125-5128	and	abstract[281]|substance[283]	new[281]|giv[283]	_	_
40-13	5129-5136	placebo	abstract[281]|substance[283]|person|substance[288]	new[281]|giv[283]|giv|giv[288]	coref	43-18
40-14	5137-5144	product	abstract[281]|substance[283]|substance[288]	new[281]|giv[283]|giv[288]	_	_
40-15	5145-5148	was	_	_	_	_
40-16	5149-5157	detected	_	_	_	_
40-17	5158-5163	after	_	_	_	_
40-18	5164-5165	4	time[289]	giv[289]	_	_
40-19	5166-5171	weeks	time[289]	giv[289]	_	_
40-20	5172-5174	of	time[289]	giv[289]	_	_
40-21	5175-5184	treatment	time[289]|event	giv[289]|giv	_	_
40-22	5185-5186	(	_	_	_	_

#Text=Figure 4
41-1	5187-5193	Figure	abstract[291]	new[291]	_	_
41-2	5194-5195	4	abstract[291]	new[291]	_	_

#Text=) .
42-1	5196-5197	)	_	_	_	_
42-2	5198-5199	.	_	_	_	_

#Text=The cream containing trehalose and ceramides based ingredient is able to improve skin hydration if compared to placebo .
43-1	5200-5203	The	substance[292]	giv[292]	_	_
43-2	5204-5209	cream	substance[292]	giv[292]	_	_
43-3	5210-5220	containing	substance[292]	giv[292]	_	_
43-4	5221-5230	trehalose	substance[292]|substance	giv[292]|giv	_	_
43-5	5231-5234	and	substance[292]	giv[292]	_	_
43-6	5235-5244	ceramides	substance[292]|substance|substance[295]	giv[292]|giv|giv[295]	_	_
43-7	5245-5250	based	substance[292]|substance[295]	giv[292]|giv[295]	_	_
43-8	5251-5261	ingredient	substance[292]|substance[295]	giv[292]|giv[295]	_	_
43-9	5262-5264	is	_	_	_	_
43-10	5265-5269	able	_	_	_	_
43-11	5270-5272	to	_	_	_	_
43-12	5273-5280	improve	_	_	_	_
43-13	5281-5285	skin	object|abstract[297]	giv|giv[297]	_	_
43-14	5286-5295	hydration	abstract[297]	giv[297]	_	_
43-15	5296-5298	if	_	_	_	_
43-16	5299-5307	compared	_	_	_	_
43-17	5308-5310	to	_	_	_	_
43-18	5311-5318	placebo	person	giv	_	_
43-19	5319-5320	.	_	_	_	_

#Text=Transepidermal Water Loss ( TEWL )
44-1	5321-5335	Transepidermal	abstract[299]	giv[299]	_	_
44-2	5336-5341	Water	abstract[299]	giv[299]	_	_
44-3	5342-5346	Loss	abstract[299]	giv[299]	_	_
44-4	5347-5348	(	_	_	_	_
44-5	5349-5353	TEWL	abstract	giv	_	_
44-6	5354-5355	)	_	_	_	_
